Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dancing with atrial fibrillation - How arrhythmia affects everyday life of family members: A qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Psychiatric disorders in individuals with neurofibromatosis 1 in Denmark: A nationwide register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Investigation of gene-environment interactions in relation to tic severity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Nationwide Cohort Study of Nonrandom Mating in Schizophrenia and Bipolar Disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  • INDICES
View graph of relations

Randomized placebo-controlled trials have reported efficacy of methylphenidate (MPH) for Attention-deficit/hyperactivity disorder (ADHD); however, selection biases due to strict entry criteria may limit the generalizability of the findings. Few ecologically valid studies have investigated effectiveness of MPH in representative clinical populations of children. This independently funded study aims to describe treatment responses and their predictors during the first 12 weeks of MPH treatment using repeated measurements of symptoms and adverse reactions (ARs) to treatment in 207 children recently diagnosed with ADHD. The children were consecutively included from the Child and Adolescent Mental Health Centre, Mental Health Services, The Capital Region of Denmark. The children (mean age, 9.6 years [range 7-12], 75.4% males) were titrated with MPH, based on weekly assessments of symptoms (18-item ADHD-rating scale scores, ADHD-RS-C) and ARs. At study-end 187 (90.8%) children reached a mean end-dose of 1.0 mg/kg/day. A normalisation/borderline normalisation on ADHD-RS-C was achieved for 168 (81.2%) children on the Inattention and/or the Hyperactivity-Impulsivity subscale in week 12, and 31 (15.0%) children were nonresponders, which was defined as absence of normalisation/borderline normalisation (n = 19) or discontinuation due to ARs (n = 12), and eight (3.8%) children dropped out from follow-up. Nonresponders were characterised by more severe symptoms of Hyperactivity-Impulsivity and global impairment before the treatment. ARs were few; the most prominent were appetite reduction and weight loss. A decrease in AR-like symptoms during the treatment period questions the validity of currently available standard instruments designed to measure ARs of MPH. This ecologically valid observational study supports prior randomized placebo-controlled trials; 81.2% of the children responded favourably in multiple domains with few harmful effects to carefully titrated MPH. Clinical trial registration: ClinicalTrials.gov with registration number NCT04366609.

Original languageEnglish
Article numbere0253727
JournalPLoS One
Volume16
Issue number10
Pages (from-to)e0253727
ISSN1932-6203
DOIs
Publication statusPublished - 21 Oct 2021

ID: 68545786